{
    "id": 25736,
    "fullName": "CD47 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CD47 positive indicates the presence of the CD47 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 961,
        "geneSymbol": "CD47",
        "terms": [
            "CD47",
            "IAP",
            "MER6",
            "OA3"
        ]
    },
    "variant": "positive",
    "createDate": "11/13/2016",
    "updateDate": "07/31/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9221,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Hu5F9-G4 induced macrophage-mediated phagocytosis of primary acute myeloid leukemia (AML) cells in culture, and eliminated AML cells in patient-derived xenograft animal models (PMID: 26390038).",
            "molecularProfile": {
                "id": 26776,
                "profileName": "CD47 positive"
            },
            "therapy": {
                "id": 4947,
                "therapyName": "Hu5F9-G4",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7028,
                    "pubMedId": 26390038,
                    "title": "Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26390038"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9213,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Hu5F9-G4 demonstrated safety and preliminary efficacy, resulted in CD47 receptor occupancy and stable disease in 12.5% (2/16) of patients with solid tumors (J Clin Oncol 34, 2016 (suppl; abstr 3019)).",
            "molecularProfile": {
                "id": 26776,
                "profileName": "CD47 positive"
            },
            "therapy": {
                "id": 4947,
                "therapyName": "Hu5F9-G4",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7029,
                    "pubMedId": null,
                    "title": "A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers.",
                    "url": "http://meetinglibrary.asco.org/content/162472-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9222,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Hu5F9-G4 and Rituxan (rituximab) synergistically eliminated tumors in cell line xenograft animal models of non-Hodgkin lymphoma (PMID: 26390038).",
            "molecularProfile": {
                "id": 26776,
                "profileName": "CD47 positive"
            },
            "therapy": {
                "id": 4955,
                "therapyName": "Hu5F9-G4 + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 60060,
                "name": "non-Hodgkin lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7028,
                    "pubMedId": 26390038,
                    "title": "Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26390038"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26776,
            "profileName": "CD47 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}